Published in Surgery Litigation and Law Weekly, June 17th, 2005
Importantly, several studies have shown that women treated with hormonal therapy in the adjuvant breast cancer setting are at risk of bone loss. This new data from the Zometa-Femara Adjuvant Synergy Trial (Z-FAST) study offers evidence that Zometa may prevent bone loss in these patients. The final data demonstrate a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.